SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

AVEO Pharmaceuticals, Inc. (AVEO)

AVEO RSS Feed
Add AVEO Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 5/24/2017 5:34:53 PM - Followers: 81 - Board type: Free - Posts Today: 0

AVEO ONCOLOGY, Inc. (AVEO) 


Company website: 
http://www.aveooncology.com/

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).


   

Product pipeline candidates include tivozanib, ficlatuzumab, AV-203 and AV-380.
 
 

AV-380 (GDF-15 Program)

In August 2015, AVEO announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro- inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States.

Tivozanib

Tivozanib, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in renal cell carcinoma and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. In addition, promising biomarker results were observed in a Phase 2 study of tivozanib in colorectal cancer.

In August of 2014, AVEO regained all rights to tivozanib. In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye. In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.

AVEO is interested in collaborating with potential partners who share our vision for cancer drug development and positively impacting patients’ lives. Please contact AVEO aveobd@aveooncology.com to discuss partnership opportunities with AVEO’s development pipeline.

Ficlatuzumab

Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) inhibitory antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities.

AVEO and Biodesix, Inc. have a worldwide agreement to develop and commercialize ficlatuzumab, with VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO and Biodesix are conducting a proof-of-concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using BDX001, a serum protein test similar to the VeriStrat test.

An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints
 

AV-203

AVEO scientists have demonstrated through the use of our Human Response Platform™ the importance of ErbB3 in promoting tumor growth. An increasing body of evidence also implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers.

AVEO has successfully completed a Phase 1 safety study showing no dose limiting toxicities at maximum dose of 20mg/kg and CLIA (Clinical Laboratory Improvements Amendment) validation has been completed for a biomarker for potential patient selection.


 
www.aveopharma.com
Shares Outstanding   55,070,000
Institutional Ownership  31%
57 Employees
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
 
  
One Broadway 14th Floor
Cambridge, MA 02142

Investor Relations
Phone: 617-588-1960
E-mail: ir@aveooncology.com

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVEO
Current Price
Volume:
Bid Ask Day's Range
AVEO News: AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma 05/19/2017 07:00:00 AM
AVEO News: Additional Proxy Soliciting Materials (definitive) (defa14a) 05/17/2017 04:31:18 PM
AVEO News: Current Report Filing (8-k) 05/17/2017 04:29:35 PM
AVEO News: AVEO Announces Appointment of Matthew Dallas as Chief Financial Officer 05/16/2017 07:00:00 AM
AVEO News: AVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer 05/15/2017 09:30:00 AM
PostSubject
#1839  Sticky Note $AVEO recent news/filings mick 11/17/15 10:42:39 AM
#2518   * * $AVEO Video Chart 05-24-17 * * ClayTrader 05/24/17 05:05:51 PM
#2517   if this gets approval overseas, theres upside to harry crumb 05/22/17 09:52:12 PM
#2515   this is a good thing people, patience! harry crumb 05/19/17 05:23:19 PM
#2514   AVEO Oncology Announces Completion of a CHMP Oral ProfitScout 05/19/17 09:19:14 AM
#2513   ANOTHER $250,000 SALARY.... JUST WHAT THESE IDIOTS NEED Apophis 05/17/17 01:59:10 PM
#2512   AVEO Announces Appointment of Matthew Dallas as Chief ProfitScout 05/16/17 09:18:05 AM
#2511   Don't forget folks, do not vote at all Full Contact Yoga 05/15/17 11:37:21 AM
#2509   AVEO News: AVEO Oncology Announces Receipt of USPTO mick 05/11/17 12:12:27 PM
#2508   Aveo Pharmaceuticals (AVEO) mick 05/11/17 12:12:20 PM
#2506   Not really. Just means Bailey couldn't pay the Full Contact Yoga 05/08/17 09:55:36 AM
#2505   AVEO Oncology Announces Receipt of USPTO Notice of ProfitScout 05/08/17 09:04:30 AM
#2504   Novartis' confidence is high with AV-380, as it twistedfreak 05/04/17 05:18:21 PM
#2503   I guess we'll have to see how this twistedfreak 05/04/17 04:27:21 PM
#2502   The RS will happen, no doubt about it. Full Contact Yoga 05/04/17 04:08:06 PM
#2501   I'd have to disagree with you. The downward twistedfreak 05/04/17 03:47:12 PM
#2500   He's done nothing, but fail, and schedule RS's Full Contact Yoga 05/04/17 03:12:23 PM
#2499   what has or hasn't he done to your liking? twistedfreak 05/04/17 02:50:08 PM
#2498   Bailey sucks, time to replace him with someone Full Contact Yoga 05/04/17 09:49:56 AM
#2497   AVEO Reports First Quarter 2017 Financial Results and ProfitScout 05/04/17 09:07:17 AM
#2496   Possible, but it will be short lived given Full Contact Yoga 04/30/17 02:17:21 PM
#2495   $AVEO could breakout any day, MACD crossed and Stockcaller 04/24/17 08:31:17 PM
#2494   AVEO Announces Presentations at the 2017 ASCO Annual Meeting ProfitScout 04/20/17 11:04:51 AM
#2493   thank you, happy easter mick 04/15/17 02:32:01 PM
#2492   Nothing to celebrate really, raised AS, another RS, Full Contact Yoga 04/14/17 10:34:08 PM
#2491   thank you, happy easter $AVEO mick 04/14/17 08:09:16 PM
#2490   Only way to block the action is to Full Contact Yoga 04/14/17 07:00:11 PM
#2489   Another RS, typical Bailey, absolute worthless POS. Full Contact Yoga 04/14/17 06:50:59 PM
#2488   AVEO Announces Submission of Response to Tivozanib Marketing ProfitScout 04/13/17 08:54:58 AM
#2487   Downgraded within Nasdaq, lowest tier, but, not sent Full Contact Yoga 04/12/17 09:49:57 AM
#2486   Yes, it was a negative catalyst, a greatly Full Contact Yoga 04/10/17 10:38:08 AM
#2485   Correctum : Just found out that 10 insiders Cclr0007 04/10/17 05:10:18 AM
#2484   Did management recently purchase $6,000,000 worth of shares Cclr0007 04/10/17 04:52:48 AM
#2483   Aveo Pharmaceuticals (AVEO) mick 04/07/17 11:35:09 PM
#2482   They can still go down a tier within Full Contact Yoga 04/07/17 12:01:00 PM
#2481   That's what I was thinking also. Appreciate it. tonyjh 04/06/17 11:50:00 PM
#2480   Aveo will do a reverse split before they Valensio 04/06/17 09:32:49 PM
#2479   When do they notify shareholders of the extension tonyjh 04/06/17 09:27:50 PM
#2478   The dilution may have raised enough capital to Apophis 04/06/17 11:02:33 AM
#2477   Look to the history of different biotech companies: alexander77 04/05/17 07:43:47 AM
#2476   Gotcha. I was a bit confused with the tonyjh 04/04/17 07:58:06 PM
#2475   that makes absolutely no sense alexander. Makes more twistedfreak 04/03/17 09:20:25 AM
#2474   No Tony. NEA and those buyers bought a twistedfreak 04/03/17 09:16:34 AM
#2473   AVEO Announces Milestone Payment from CANbridge for AV-203 ProfitScout 04/03/17 09:14:50 AM
#2472   Loool,they just received a $1m milestone payment. Probably alexander77 04/03/17 07:12:19 AM
#2471   Question if you don't mind, if the OS tonyjh 03/30/17 05:40:05 PM
#2470   AVEO bullish 0.6019 stocktrademan 03/30/17 01:59:16 PM
#2469   AVEO News: Statement of Changes in Beneficial Ownership mick 03/29/17 08:11:24 PM
#2468   Owners...right on. tonyjh 03/29/17 04:45:39 PM
#2467   Accumulation is underway in a big way and twistedfreak 03/29/17 11:58:29 AM
#2466   Appreciate your thoughts. Is it me, or does tonyjh 03/29/17 10:52:14 AM
PostSubject